Life Sciences Archive » April, 2019

Life Sciences - April, 2019

321 articles

• Keryx Investors Seek Class Cert. In Kidney Drug Stock Case
• G&E, Saxena White Win Lead In Nerve-Repair Investor Suit
• Monsanto Expert Testifies Roundup Is Safe Without Gloves
• Senators Float Bill To Make FTC Study Pharmacy Managers
• FDA Slaps Black Box Warning On Ambien, Other Sleep Drugs
• EPA Reaffirms Glyphosate Safety, Proposes Usage Changes
• DOJ Denies 'Antipathy' For FCA Whistleblower Co.
• Pay-For-Delay Ban, Other Drug Price Bills Advance In House
• With Opioid Charges, DOJ Signals Compliance Fixation
• FDA Allows Philip Morris To Market Tobacco 'Heatsticks'
• Pharma Co. Inks $17.5M Deal To End FCA Kickback Suit
• 2nd Circ. Affirms Toss Of Endo Securities Class Action
• Colgate Offered 'Sham Witness' In ERISA Suit, Workers Say
• Pa. Judge Doubts Conflict In Attys' Dual Level Opioid Work
• REIT, Biotech And Tech Startups Launch IPOs Totaling $215M
• AI Is Forcing FDA Medical Device Rules To Evolve
• Missing Elements From New Cannabis Banking Bill
• Monsanto Expert 'Micro-Analyzed' By Atty At Roundup Trial
• Endo Not Liable In Pa. For Defective Mesh Made By Subsidiary
• FDA Stalling On Impulsivity Warnings For Drugs: Nonprofit
• Pfizer Exec Seeks Justices' Take On ERISA Venue Selection
• BakerHostetler Snags Ex-Dinsmore IP Partner In DC
• Medtronic Can't Get Fed. Circ. Redo On $24M Spine IP Loss
• NECC Pharmacists Not At Fault For Fake Orders, Jury Hears
• 7 Cos. Heat Up IPO Pipeline With Nearly $1B In Deals
• Filing For Bankruptcy To Manage Opioid Suits Is No Magic Pill
• A Chat With Cleary Chief Talent Officer Hy Pomerance
• J&J Talc Supplier Argues For Its Future Claims Rep Choice
• Atty Sanctions Axed In Opioid MDL, Allowing Doc's Testimony
• DOJ Asks 7th Circ. To Revive Becton Price-Fixing Suit
• Bayer CEO Says Company Faces 13,400 Roundup Suits
• Del. Judge Tosses Bard's $67.5M Vascular Port IP Case
• Fed. Circ. Upholds Eli Lilly's Alimta Vitamin Regimen IP
• 11 Firms To Guide 7 IPOs Exceeding $1B To Start May
• Feds Likely To Try Again If Insys Jury Deadlocks
• FDA's Risk Evaluation Guidance Brings Clarity, Not Solutions
• Forced Arbitration Is A Far Worse 'Product' Than Jury Trials
• Bayer Is Still Fighting 'Flanax,' More Than A Decade Later
• Biotech Co. Faces Investor Suit Over 'Misleading' Merger Info
• Scrutiny Of Physician-Owned Distributors Is Far From Over
• Preet Bharara On The Human Factor In The Justice System
• Monsanto Faces Uphill Fight In Axing Punitives From Trial
• Opioid MDL Attys' Concealment Merited Sanction: Drug Cos.
• TridentUSA Ch. 11 Plan Faces Early, Multipronged Opposition
• J&J Trashes 'Radical' Okla. Opioid Case As Trial Looms
• Novartis Settles Suit Saying Janssen Maligned Rival Drug
• Kimberly-Clark Whistleblower Seeks Revival Of Axed FCA Suit
• Okla. Cities Not Bound By Purdue's Opioid Deal, Judge Says
• PacBio DNA Patent Suit Survives Dismissal Push
• Whistleblower Won't Get Atty-Client Docs In Debt Deal Suit
• OFCCP Case Changes The Game For Contractor Pay Audits
• Skadden, Latham Steer 2 Follow-On Offerings Raising $152M
• GSK Plans $100M Mont. Vaccine Production Site Expansion
• GTx Shareholder Sues To Block Oncternal Merger
• Competitive Generic Therapy Exclusivity Offers Benefits
• Astellas, Amgen To Pay $125M To End Kickback Probe
• J&J, Colgate's Talc Cancer Link 'Makes Sense,' Jury Told
• Monsanto Appeals $78.5M Loss In First Roundup Trial
• FTC Accuses Electronic Prescription Co. Of Monopolization
• After 10 Days Of Jury Silence, Insys Exec Asks To Go Home
• Philly Jury Slams J&J With $120M Award In Mesh Injury Case
• Investor Sues Boston Scientific Over FDA's Mesh Product Pull
• FDA Urged To Crack Down On Anti-Smoking Supplements
• Gene Therapy Co. Hit With Suit Over $877M Sale To Biogen
• Drug Lobby Says Athena Ruling May Zap Biotech Funding
• Colgate Tells Jury In Talc Cancer Trial Its Mines Asbestos-Free
• What Drove DOJ's 1st Opioid Distributor Charges?
• Jury Trials, Though In Decline, Are Well Worth Preserving
• Amazon Gets Customer's Walker Injury Suit Trimmed
• Allergan Drug Buyers Take One Last Shot At Class Cert.
• Big Biz Universally Beefing Up Compliance Units, KPMG Finds
• Synergy Pharmaceuticals Wins Ch. 11 Plan Approval
• J&J, Bausch Reach Talc Litigation Deal
• Cooley-Led Biotech Nixes IPO, Scores $142M Funding Round
• Ex-Aveo CFO Says Securities Fraud Verdict Should Be Tossed
• Pet Medicine Cos.' Suit To Block Rivals' Tie-Up Tossed
• A Broader View Of The US Supreme Court Bar
• Ex-Shkreli Atty Splitting Hairs Over 'Duty,' Gov't Says
• Diplomat Pharmacy Inks $14M Deal In Suit Over PBM Fees
• PE Firm Plugs $100M Into Medical Imaging Co. NorthStar
• DOJ Unveils 1st Criminal Charges Against Opioid Distributor
• J&J And Colgate Face Latest Talc Trial Together In Calif.
• Feds Seek Pause Of SEC's Civil Suit Against Theranos Official
• J&J Settles Wash. AG's Pelvic Mesh Case Just Before Trial
• Aveo Pharma Stock-Drop Suit Lands In Massachusetts
• Pfizer VP Returns To DLA Piper As Litigation Partner In DC
• Deals Rumor Mill: Dassault, Cerberus, Bain
• Insurers Seek To Lift Stay Amid J&J Talc Injury Suits
• J&J Butter Buyers Denied Cert. In 'No Trans Fat' Labeling Suit
• 4 Firms Seek To Lead Ranbaxy Antitrust MDL In Boston
• 4 Cos. Launch IPOs Totaling $650M Led By Mobile Games Biz
• Inside DOJ's Recent Charitable Copay Foundation Settlements
• Philly The Proper Venue For Kratom Death Case, Judge Rules
• New USPTO Guidance May Help Diagnostics Patents
• 15 Minutes With AbbVie's Chief Legal Officer
• Fed. Circ. Affirms PTAB Ax Of Hologic Medical Device Patent
• US Trustee Fights Bid To Seal Worker Info In 'Superbug' Ch. 11
• Meet The 'Wonder Drug' Drawing FDA Fire
• Blue Cross Attacks Janssen Prostate Cancer Drug 'Monopoly'
• J&J Says 2,400 Talc Suits Belong In Del. Federal Court
• J&J Win Shows Potential Limit To Mesh Injury Claims
• Opioid MDL Shouldn't Hold Up NJ County's Suit, Court Told
• X-Ray Engineer Gave Trade Secrets To Rival, Philips Says
• In Virtual Teams For Mass Torts, The 'Law Team' Is Critical
• Takeaways From DOJ Action Against Telemedicine Fraud
• McKesson To Pay $1.6M In Back Wages, Benefits, DOL Says
• Answers To AI Patent Questions May Be Found In Biotech
• Polsinelli Adds Boston Biotech IP Attys From Wolf Greenfield
• 5 Tips For Lawyers Entering The Cannabis Industry
• Health Hires: DLA Piper, McDermott, Barnes & Thornburg
• 5 Times Lawyers Settled During The Big Show
• Doc Linked To Insys Denies New Charges In Patient's Death
• Postpone Opioid MDL Trial? Get Real, Judge Says
• USPTO Patent Eligibility Rejections Fall Under New Guidance
• Breaking Down 3 New Senate Bills Targeting Drug Prices
• Deals Rumor Mill: Ancestry, Advent, Acuris
• AmerisourceBergen Investors Demand Opioid Crisis Records
• Lathrop Gage Nabs IP Pro From Sunstein Kann
• PE-Backed Medical Tech Co. Files Simpson Thacher-Led IPO
• The Big Picture: How #MeToo Is Changing The Legal Industry
• Jury Trials Are In Decline For Good Reason
• Atty Fees, Costs Approved in $3.3M Lion Biotech Deal
• AutoMedx Says Zoll's $5.4M Suit Is Barred By Bankruptcy
• Genetic Testing Is On FTC's Radar
• Fidelity Brokerage Immune From Market Case: 1st Circ.
• EPA Approved Roundup Based On Bogus Studies, Jury Told
• Insurance Co. Wants To Depose Retired Judge In Stryker Row
• Neovasc Will Add CardiAQ Founders To Patents To End Suit
• Feds Slam Order To Cough Up Info In Kickbacks Suit
• Fed. Circ. Keeps PTAB Ax Of Purdue OxyContin Patent Claims
• Escape Hatch Remains For Judges Accused Of Misconduct
• DOJ Dismissal Power Looking Wobbly In FCA Cases
• Cancer Biotech, 2 Others Score IPOs Totaling $279M
• Celgene Wants Sun Pharma's Revlimid Generic Blocked
• Justice Dept. Charges 60 In Appalachia Opioid Sweep
• BioPharma Firm, Device Maker Blocked Generic, Sandoz Says
• UK Spots Issues With Thermo Fisher $925M Microscope Deal
• Attys Re-Up Bid To Drop Avenatti From $450M Class Action
• Biologic Manufacturers Should Expect Antitrust Scrutiny
• Federal Courts' #MeToo Response Is A Guide For State Courts
• J&J Dodges Pelvic Mesh Claims In Philadelphia Trial
• Few Avenues To Protection For Foreign FCPA Whistleblowers
• 'Superbug' Pharma Firm Seeks Quick OK On Ch. 11 Bonuses
• Riding #MeToo Wave, State Courts Get Their Ships In Order
• Bayer Exec Denies Knowing Of Ghostwriting At Roundup Trial
• EEOC's Lipnic On Sexual Harassment In The Courthouse
• CVS To Pay $535K To End Allegations Of Bogus Percocet Rx
• Ex-Theranos CEO Says Feds Are Stonewalling Over Docs
• J&J's Rush To Market Made Mesh Patients Suffer, Jury Told
• Opioid MDL Attys Say Sanction 'Does Not Fit The Crime'
• FDA Orders Surgical Mesh Products Pulled From US Market
• Why I Became A Lawyer: A Circuitous Path To The Law
• Cooley-Led Tech Unicorn, Biotech Firm Raise IPO Targets
• Wilson Sonsini Adds Life Sciences Veterans From Arent Fox
• 4 Tips For Global Patient Support Compliance: Part 2
• Indirect Buyers Can't Bring Antitrust Suit, Dental Cos. Say
• Zoll Says Ex-Partners Can't Escape $5M Arbitration Award
• Trade Secrets Suit Against Mitsui Severely Trimmed
• DOJ Sees 'Arbitrary' FCA Dismissal Bid Rejected
• Discipline Rare For State Judges In Sexual Misconduct Cases
• Wall Of Secrecy Surrounds Sexual Harassment In State Courts
• Judge Will Let Cameras Roll In Okla. Opioid Trial
• High Court Gives Thumbs-Down To 3 Employment Cases
• Channel CEO Stunned At Boston Scientific's Deal Rebuff
• 9 Companies File IPOs To Bolster May Pipeline
• Tainted Scopes Related To 3 More Deaths, FDA Says
• Deals Rumor Mill: AB InBev, Chi-Med, Biohaven Pharma
• Judging A Book: Conrad Reviews 'The Jury Crisis'
• 'Superbug'-Fighting Pharma Firm Hits Ch. 11 With Sale Plans
• 5th Circ. Upholds 3-Year Medicaid Ban For 2 Texas Docs
• High Court Passes On Tribal Immunity, Alice Timing, 'Empire'
• Mass. Judge Upholds Convictions For 2 NECC Pharmacists
• 4 Firms Spearhead $1.2B Catalent-Paragon Bioservices Deal
• Insys CEO Resigns Amid Uncertain Future
• Robocall Damages Against Marketer Could Hit $925M
• Adult Diaper Co. Must Pay For Worker Retaliation In FCA Suit
• 15 Firms To Steer Robust IPO Lineup Led By Pinterest
• Zimmer Biomet Investors Seek Class Cert. In Stock-Drop Suit
• Allergan Drug Buyers' Renewed Bid For Cert. Deemed 'Futile'
• Texas Senate Passes Bill Cracking Down On Legal Ads
• Teva, J&J Face Opioid Trial In 'Unreasonably Small' Courtroom
• Allergan, St. Regis Ask Justices To End 'Blocking Patent' Rule
• Asbestos Experts Were Cut For 'Parroting' Others, Judge Says
• Judge Won't Certify Perrigo's Appeal In Drug Price-Fixing MDL
• No Shortage Of Opinions On New USPTO Eligibility Guidance
• Cannabis Banking Bill Is Promising, But Limited In Scope
• Bristol-Myers Wins Investor Support For $74B Celgene Buy
• Med Device Biz Investor Ajax Scores $85M In Funding Push
• Revamping Your Approach To Client Development
• Monsanto Tested Roundup Using 'Dumb' Assumptions: Expert
• Trump Admin Moves To Rein In Agency Guidance Materials
• U.S. Trustee Takes Aim At Imerys' Ch. 11 Asbestos Claims Rep
• 5 Things To Watch As Indivior Attacks DOJ Opioid Indictment
• Pa. Panel Backs Woman's $13.5M J&J Mesh Injury Award
• 'Pharma Bro' Shkreli Can't Duck Kidney Drug Antitrust Suit Yet
• AbbVie To Settle With Shire Investors Over Failed $55B Tie-Up
• Jefferies Urges Court To End Investors' Suit, Sanction Attys
• FDA Seeks More Data On Hand Sanitizer Ingredient Safety
• 4 Tips For Global Patient Support Compliance: Part 1
• What Lawyers Must Know Before Acting As Escrow Agents
• Two Firms Steer Cybersecurity Software Co. To $108M IPO
• Who Can Be A Defendant In Biosimilar Patent Litigation?
• Bonuses, Debt Claims Probe OK'd In TridentUSA Ch. 11
• No More Trial Delays In Opioid MDL, Judge Says
• Sandoz Says Antitrust Row Can't Hinge On Drug Patent Case
• Pa. Justices To Mull Standing For Out-Of-State Mesh Patients
• FTC's Impax Decision Shows Hard Line On Reverse Payments
• Orrick Nabs Former Co-Chair Of MoFo's Life Sciences Group
• Acorda Asks Justices To Abolish 'Blocking Patent' Doctrine
• Johns Hopkins, Bristol-Myers Want Sanctions In Syphilis Suit
• Deals Rumor Mill: VW, QSR Brands, BioTek
• McGuireWoods Snags Ex-Faegre Health Pro
• FTC Makes $25M Deals With 'Viagra For Your Brain' Sellers
• Plan Sponsors Should Beware Hidden Costs From PBMs
• Tax-Dodging Exec's Hail Mary Bid For Less Prison Time Fails
• Execs, MDs Charged In $1.2B Medicare Fraud Scheme
• Roundup's Link To Cancer 'Not A Hard Call,' Jury Hears
• Ex-Attys Seek To DQ New Counsel Handling $350M Shire Deal
• FDA Exclusivity View Blocking Opioid Treatment, Suit Says
• Indivior Indicted Over Opioid Treatment Marketing Fraud
• Ill. AG Is Latest To Sue Purdue Over Opioid Crisis
• Medical Supplier Dodges Spousal Bias Claims At 8th Circ.
• Dickinson Wright Adds Chemist-Turned-Patent Pro As Partner
• PTAB Axes Hair Loss Treatment Patent In Incyte Challenge
• Opana Buyers Seek Class Cert. In Pay-For-Delay Row
• The Biggest Deals From Q1 & The Firms That Led Them
• Freelance Attorneys Are An Asset To In-House Legal Teams
• Real Estate Rumors: Ventas, SDG, Copart Of Connecticut
• Synergy Shareholders End Ch. 11 Objections For $1.4M
• Don't Discount Drug Discounting
• CBD Scrutiny May Signal Broader FDA Enforcement Trend
• Athena Asks Fed. Circ. To Rethink 'Evisceration' Of Patent Law
• Cancer Risk Doubles With Regular Roundup Use, Jury Told
• Janssen Needn't Show Earnings In Off-Label Use Suit
• Opioid MDL Attys Sanctioned For Hiding Doctor's Cooperation
• 5th Circ. Nixes 'Obamacare' Brief To Avoid Judge's Recusal
• Bio-Rad Cleared To Enforce Sample Protection Patents
• 4 Recent Fed. Circ. Decisions Patent Attorneys Need To Know
• Thermo Fisher's $4.7M Wage Deal Gets Green Light
• 9th Circ. Won't Rehear Bio-Rad Ex-GC's $8M Win
• Tech 'Unicorn' Tops 4 IPO Launches With $626M Deal
• Concordia Pharma Sues Over Bowel Drug Trade Secrets
• BakerHostetler Can't Overturn Opioid MDL Disqualification
• Former FDA Drug Regulatory Adviser Joins Covington In DC
• J&J's Mesh Appeal Nothing But A 'Trial Balloon,' 7th Circ. Told
• Calif. Jury Finds No Asbestos In J&J Talc
• Cancer Center's $7.2M Antitrust Deal Flawed, Court Says
• Apotex Can't Sink Amgen's IP Suit Over Drugs To Aid Chemo
• Outgoing HHS Watchdog Targeted Purdue, Paved ACA's Path
• 'Massive Scheme' Or 'Big Lie'? Insys Execs In Jury's Hands
• Pa. Stuck In Litigation Limbo As Purdue Inks 1st Opioid Deal
• Pfizer's Lyrica Update Infringes Patent, Sun Pharma Says
• Ex-Ranbaxy Owners Face Contempt Over $506M Award
• Justices Urged To Pass On Orexigen Disclosure Dispute
• OFCCP Case Sheds Light On Pay Equity Analysis Techniques
• Unanswered Questions On FDA-USDA Cell Culture Agreement
• 3rd Circ. Hands J&J Win In Applicant's Background Check Suit
• TridentUSA Creditors Clash In Pre-Bankruptcy Debt Probes
• Insys Wants Anthem Fentanyl Suit Sent To Ohio Opioid MDL
• Insys Execs Put 'Profits Over Patients,' Feds Tell Jury
• Judge Won't Stop Roundup Ads Allegedly Targeting Jury Pool
• Chancery OKs $9M Deal In Fight For Med Device Co.
• Big Opioid Case Trimmed To Beat Drugmaker 'Stall Tactics'
• PE-Backed Tradeweb Tops 3 IPOs With $1.1B Offering
• Deals Rumor Mill: Deutsche Bahn, ICG, Apotex
• DOJ Must Explain FCA Dismissals, Judge Rules
• Fed. Circ. Agrees Purdue's OxyContin Patent Is Obvious
• Fed. Circ. Ruling Clarifies Role Of USPTO Eligibility Guidance
• What High Court's Expansion Of FCA Time Limits Would Mean
• Medical Device Co. Medacta Scores $1.9B In Swiss IPO
• Care.com Hit With Shareholder Suit Over Vetting Practices
• Pharma Cos. To Pay $123M To End Medicare Kickbacks Probe
• 'Big Tech' Questions Echo Early Days Of US Corporate Law
• The Important Reasons DOJ Wants To Toss Gilead FCA Case
• Expert In Roundup Trial Says Regulators Ignored Own Rules
• CVS Loses Challenge To Sentry's Revamped Antitrust Suit
• LA Times Owner 'Caught And Killed' Cancer Drug, Suit Says
• BakerHostetler Crossed 'Ethical Line' In Opioid MDL: Gov'ts
• Roche Evades Cancer Study Stock-Drop Suit For Second Time
• Fed. Circ. Ruling Shows Limits Of USPTO Eligibility Guidance
• Pa. Superior Court Clears Way For Out-Of-State Mesh Cases
• 1 Firm Edged Ahead In March As IPOs Finally Gain Steam
• Insys Judge Says Part Of Gov't Racketeering Case Is 'Thin'
• Bid To Drop Avenatti From Class Action Fails Over Procedure
• Roche Refiles For US Antitrust Review Of $4.3B Spark Buy
• Montel Williams Settles With CBD Cos. To End Likeness Row
• Ex-Abbott Labs Worker Gets 2nd Shot At Discrimination Claim
• Fed. Circ. Affirms WaveForm's Glucose Monitoring Patents
• Medical Pot Law Is Not A Right To Grow, Fla. Court Says
• House Says Private Email Off-Limits In Collins Case
• Purdue's Sackler Family Wants 'Divisive' Mass. Suit Tossed
• Deal Nets Fla. Medical Marijuana Provider Extra Dispensaries
• Ex-Insys VP Pays $9.5M To End Ariz. Opioid Kickback Claims
• FDA Issues Warnings Over CBD Claims, Sets Public Meeting
• Hospital Says Fed. Circ. Subverting Sanctity Of Jury Verdicts
• Okla. Cities Seek To Clarify $270M Deal In Purdue Opioid Case
• Key Opioid Case On 'Untenable' Course, Teva Says
• Insys Judge Unmoved So Far By Midnight Acquittal Bid
• Pa. Counties Want Out Of Coordinated Opioid Litigation
• Tribes Get Tentative Green Light In Opioid MDL
• Tribes Urge 5th Circ. To Preserve Indian Health Law In ACA
• Highlights From 2019 ABA Antitrust Spring Meeting: Part 2
• J&J, Other Drug Cos. Fail To Shake Fla. AG's Opioid Suit
• HHS Inspector General To Resign After 15 Years
• Invisalign Maker Strikes $35M Deal With Rival In IP Fight
• Novo Nordisk Investors Seek Cert. In Insulin Pricing Suit
• Kisor Case May Positively Disrupt Technological Governance
• Gibson Dunn Health Chair Tapped As Catholic U. Law Dean
• FDA Focus: What Latham's Practice Chair Is Watching
• NY, Fla. Buyers Get Cert. In Gerber Formula False Ad Suit
• BioPharma Co. Ducks Stock-Drop Suit Over Presentation Hype
• 2 Republican AGs Break Rank, Back ACA At 5th Circ.
• DOJ's Novartis Kickback Case Cleared For Trial
• Ligand Pushes Chancery To Squelch $4B Formula-Botch Suit
• High Court Again Refuses To Revisit FCA Materiality
• Judge Botched BakerHostetler DQ In Opioid MDL, Endo Says
• Insys Drug Was 'Amazing' For Pain, Patient Tells Jury
• FDA Looks To End Athenex's Active Ingredient Suit
• Highlights From 2019 ABA Antitrust Spring Meeting: Part 1
• Fed. Circ. Rules 2 Cleveland Clinic Test Patents Ineligible
• 3 Firms Steer $260M Deal For Migraine Drug Royalty Interest